Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026)
Disc Medicine's (IRON) quarterly Income from Continuing Operations came in at 63553000.0 in Q1 2026, down 87.11% year-on-year from 492953002.51 in Q1 2025, and down 305.13% on a QoQ basis from 15687000.0 in Q4 2025.
Disc Medicine (IRON) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has 7 years of Income from Continuing Operations data on file, last reported at 63553000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 87.11% year-over-year to 63553000.0 in Q1 2026; TTM through Mar 2026 was 196756000.0, a 68.81% decrease from a year earlier, with the FY2025 full-year figure at 167340000.0, down 53.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 63553000.0, down from 15687000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IRON reached as high as 9580000.0 in Q2 2022 and fell as low as 63553000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27266411.76 across 5 years, with a median of 23546000.0 in 2023.
- Across the five-year window, Income from Continuing Operations sank 155.96% in 2022 and surged 47.07% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11244000.0 in 2022, then slumped by 109.41% to 23546000.0 in 2023, then decreased by 25.86% to 29636000.0 in 2024, then jumped by 47.07% to 15687000.0 in 2025, then slumped by 305.13% to 63553000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 63553000.0 in Q1 2026, 15687000.0 in Q4 2025, and 62321000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Disc Medicine | 2.90 Bn | 2.90 Bn | - | -63.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.55 Mn |
| Dec 31, 2025 | -15.69 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.20 Mn |
| Mar 31, 2025 | -33.97 Mn |
| Dec 31, 2024 | -29.64 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.35 Mn |
| Mar 31, 2024 | -26.94 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.12 Mn |
| Jun 30, 2023 | -16.00 Mn |
| Mar 31, 2023 | -22.78 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 20.09 Mn |
| Sep 30, 2021 | -18.55 Mn |
| Jun 30, 2021 | -16.42 Mn |